Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes
PARTNERSHIP LEVERAGES IPSC-BASED BETA CELLS FROM EVOTEC'S QRBETA INITIATIVE COMBINED WITH SERNOVA'S PROPRIETARY IMPLANTABLE CELL POUCH™ DEVICETHE GOAL IS THE DEVELOPMENT AND COMMERCIALISATION OF AN OFF-THE-SHELF BETA CELL REPLACEMENT THERAPY FOR …
- PARTNERSHIP LEVERAGES IPSC-BASED BETA CELLS FROM EVOTEC'S QRBETA INITIATIVE COMBINED WITH SERNOVA'S PROPRIETARY IMPLANTABLE CELL POUCH™ DEVICE
- THE GOAL IS THE DEVELOPMENT AND COMMERCIALISATION OF AN OFF-THE-SHELF BETA CELL REPLACEMENT THERAPY FOR INSULIN-DEPENDENT DIABETES
- EVOTEC MAKES STRATEGIC € 20 M EQUITY INVESTMENT IN SERNOVA
- EVOTEC/SERNOVA JOINT CONFERENCE CALL AND WEBCAST AT 8.30 AM EDT MAY 17, 2022
HAMBURG, GERMANY, and LONDON, ON / ACCESSWIRE / May 17, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Sernova Corp. (TSX-V: SVA; OTCQB: SEOVF; FSE: PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics today announced a partnership in the field of diabetes. Both Companies will leverage their respective strengths to develop an implantable iPSC-based beta cell replacement therapy for the treatment of insulin-dependent diabetes, including type 1 and 2.
The partnership leverages iPSC-based beta cells from Evotec's QRbeta initiative. Evotec reliably produces human iPSC-based beta cells in islet-like clusters in a quality controlled ("QC") scalable bioreactor process. Those islet-like clusters are functionally equivalent to primary human islets in their ability to normalise blood glucose levels in in vivo models over several months.
Lesen Sie auch
Evotec's iPSC-based beta cells will be combined with Sernova's proprietary Cell Pouch™, which is the leading implantable and scalable medical device in its class. In particular, it enables vascularisation of the cell implant and thus ensures long-term survival and optimal function in patients. The combination of primary donor islets and Cell Pouch has achieved long-lasting therapeutic results in patients enrolled in Sernova's US-based Phase I/II clinical trial, including sustained insulin-independence in high-risk Type 1 Diabetes patients who previously required insulin injections for survival. Moreover, Sernova will evaluate local immune protection technology to protect non-modified beta cells and avoid the requirement for immunosuppressive treatment. The goal of the partnership is the development of an off-the-shelf iPSC-based beta cell replacement therapy device for the treatment of patients living with insulin-dependent diabetes.